HIMS

Hims & Hers Health raised its full-year 2026 revenue guidance to $3.1-$3.3 billion after Q2 revenues of $753.2 million beat estimates, though a 10-cent per-share loss exceeded consensus. The company is pivoting to an AI-

Hims & Hers Health shares fell nearly 7% in premarket trading after the company reported a second-quarter net loss of $86.29 million, or $0.37 per share, swinging from net income of $42.51 million a year earlier and far

Hims & Hers Health has publicly responded to a Federal Trade Commission lawsuit challenging its telehealth practices and use of patient data, defending its handling of consultations and consumer information. The lawsuit

April's CPI surged 3.8% year-over-year, exceeding forecasts and rattling markets, with the NASDAQ down 1.2%, S&P 500 down 0.7%, and Dow Jones down 0.6%. The inflation spike, driven by energy costs tied to the Strait of H

Hims & Hers Health (HIMS) faces a new legal challenge as the FTC, Utah, and Los Angeles County sue the company for allegedly misleading consumers about subscriptions and cancellations, and sharing sensitive health data w

Hims & Hers Health stock has dropped about 35% from its recent high, even as the company pivots aggressively into branded weight-loss drugs and expands globally via acquisitions like Eucalyptus. Management reports adding

The U.S. Federal Trade Commission, joined by Los Angeles County and Utah, sued Hims & Hers on July 29, alleging the telehealth platform shared users' sensitive health data with third-party advertisers like Meta and Snap

An FDA advisory panel voted Thursday to recommend four peptides—BPC-157, KPV, TB-500, and MOTS-C—for inclusion on the 503A Bulks List, which would allow compounding pharmacies to legally produce them. The 8-6 and 7-5-2 v